Antibody CC-1 for men with returning prostate cancer
Part of Cancer clinical trials.
This Phase 1 study tests an antibody drug (CC-1) for men whose prostate cancer has come back, based on rising PSA blood tests. It looks at safety and how the treatment affects cancer activity, especially whether it can help control early biochemical recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man age 18 or older and able to follow the study plan and visits
- Your prostate cancer diagnosis must be confirmed by past biopsy/surgery results
- Your PSA rise must meet specific criteria after finishing last treatment, and repeat PSA tests must show increase
- Your scans must show no spread to distant organs on a PSMA PET scan
- Your disease should be “slow enough” based on PSA timing and biopsy grade (ISUP under 4)
- Certain blood, liver, kidney, and heart/lung health limits must be met on recent lab checks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted radiation therapy (PSMA-RLT) for men whose prostate cancer has returned after initial treatment, shown only by rising PSA levels. It aims to control the cancer without using hormone therapy.
This trial tests a new imaging injection (INR101) to help find where prostate cancer may have returned after your first treatment. It uses PET/CT scans to spot cancer cells more clearly.
This Phase 1 study tests a new drug that aims to attach to PSMA on prostate cancer cells and activate T-cells (an immune cell type) to attack the cancer. It is for men with advanced prostate cancer that no longer responds to hormone therapy, especially after several prior treatments.
This trial tests a combination of a personalized peptide vaccine and an antibody therapy for men with prostate cancer that has returned after initial treatment. The goal is to see if this approach can control the cancer without needing stronger hormone therapy.
This study tests a newer type of PET scan (fluciclovine) in men whose previous PSMA PET scan was negative or unclear. It aims to find if the fluciclovine PET can better detect where the cancer has returned, helping guide treatment decisions.
This trial tests if a second round of a targeted radiation therapy (177Lu-PSMA-617) can help men whose prostate cancer has returned after a successful first treatment. It is for men whose cancer has stopped responding to hormone therapy and chemotherapy, and whose PSA levels have risen again after a prior good response to this drug.
Hear when a new Prostate Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.